Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, Pyramid Biosciences to ID Patients With NTRK Fusion-Driven Cancers for Clinical Trial

NEW YORK – Pyramid Biosciences said Tuesday that it will join Tempus' TIME Trial Network for clinical trial patient identification under a new collaboration agreement between the two companies.

Pyramid is advancing its tropomyosin receptor kinase inhibitor, PBI-200, in a Phase I/II trial in participants with neurotrophic tyrosine receptor kinase fusion-positive advanced or metastatic tumors. The collaboration with Tempus, a company specializing in artificial intelligence for precision medicine, will support enrollment of patients for the trial.

The TIME Trial Network is a program created by Tempus to identify and match patients with clinical trials using next-generation sequencing capabilities, an analytics platform capable of identifying biomarker targets, and artificial intelligence tools. It is intended to overcome enrollment challenges encountered by many clinical trials in the precision oncology space. According to a 2017 report by the Tufts Center for the Study of Drug Development, as many as 11 percent of research sites fail to enroll a single patient.

"Our collaboration with Tempus and its TIME Trial Program allows us to further enhance our ability to precisely identify patients with NTRK fusion-positive tumors, particularly those with primary and metastatic CNS tumors," Jordan Leef, cofounder and chief business officer of Pyramid Biosciences, said in a statement.

Pyramid also partnered with Caris Life Sciences on patient identification for the PBI-200 trial under an agreement inked in March.